MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.2700
-0.0200 (-1.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.2900
Open1.3000
Bid0.0000 x 27000
Ask0.0000 x 3100
Day's Range1.2700 - 1.3100
52 Week Range0.9400 - 2.3400
Volume837,036
Avg. Volume2,267,246
Market Cap240.812M
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.3540
Earnings DateAug 9, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 9:30 am (ET) at the InterContinental New York Barclay Hotel in New York City. Presenting from the Company will be its Chief Executive Officer, Michael Castagna. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.

  • GlobeNewswire

    MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

    MannKind Corporation (MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected insulin analog (insulin aspart) therapy to assess glucose control, mealtime glucose changes, Afrezza dosing, and rates of hypoglycemia over a one-year period.

  • United Therapeutics' Trevyent NDA for PAH Accepted by FDA
    Zacks

    United Therapeutics' Trevyent NDA for PAH Accepted by FDA

    United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

  • 5 Dollar Stocks to Buy Now
    InvestorPlace

    5 Dollar Stocks to Buy Now

    U.S. equities are struggling with minor losses on Tuesday after reports Chinese officials are losing confidence in President Trump as an honest negotiator. This follows frustrations in the way the Huawei situation has been handled. China considers this a trade issue, but the U.S. calls it a security issue. * 10 Stocks to Sell in Market-Cursed September Still, key areas of the market are perking up nicely (led by energy) as buyers swoop in on beaten down names. A number of stocks trading around the $1 mark are rallying nicely, pointing to the potential for big gains for penny stocks in the days ahead. Here are five dollar stocks worth a look:InvestorPlace - Stock Market News, Stock Advice & Trading Tips MannKind Corporation (MNKD)Shares of MannKind (NASDAQ:MNKD), a biopharmaceutical company focused on treatments for ailments such as diabetes and hypertension, are emerging from a multi-month consolidation range and looks set to challenge its 200-day moving average. The company recently completed construction of a new manufacturing site for high-potency molecules. Carbo Ceramics (CRR)Shares of Carbo Ceramics (NYSE:CRR), a provider of frac products and services to the oil and gas industry, are blasting higher today rising more than 14% to move closer to its 200-day moving average. A return to the highs seen in the summer of 2018 would be worth a 5x gain from here. * 7 Best Stocks That Crushed It This Earnings Season The company will next report results on October 24 before the bell. Analysts are looking for a loss of 48 cents per share on revenues of $47.9 million. Nabors Industries (NBR)Shares of Nabors Industries (NYSE:NBR), a provider of drilling and drilling-related services to the energy industry, is enjoying a share price bounce back above its 50-day moving average.The company will next report results on October 29 after the close. Analysts are looking for a loss of 21 cents per share on revenues of $788.2 million. Dean Foods (DF)Shares of Dean Foods (NYSE:DF), a food and beverage provider focused on the sale of milk and other daily products, is enjoying a rise off of a tight five-month consolidation range. Watch for a run at the 200-day moving average, which would be worth a gain of two-thirds from here. * 10 Buy-and-Hold Stocks to Own Forever The company will next report results on November 6 before the bell. Analysts are looking for a loss of 20 cents per share on revenues of $1.9 billion. Clean Energy Fuels (CLNE)Clean Energy Fuels (NASDAQ:CLNE), a provider of compressed natural gas to vehicle fleets, is rallying off of two-month support and looks ready to return to the highs seen back in July -- which would be worth a gain of more than 20% from here. The company recently reported that quarterly earnings grew 7.7% from last year on higher volumes.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post 5 Dollar Stocks to Buy Now appeared first on InvestorPlace.

  • MannKind (NASDAQ:MNKD) Has Debt But No Earnings; Should You Worry?
    Simply Wall St.

    MannKind (NASDAQ:MNKD) Has Debt But No Earnings; Should You Worry?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WESTLAKE VILLAGE, Calif., Aug. 30, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • Zacks Small Cap Research

    MNKD: Q2 2019: Record Revenue, Margins as Rx Continue to Ramp. Clinical Evidence Driving Adoption

    MannKind Corp (MNKD) reported financial results for their second quarter ending June 30th and provided a business update. Both gross and net product sales set new records, as did product margin. As a reminder, Afrezza is sold in 4-,8- and 12-unit cartridges.

  • Thomson Reuters StreetEvents

    Edited Transcript of MNKD earnings conference call or presentation 7-Aug-19 9:00pm GMT

    Q2 2019 MannKind Corp Earnings Call

  • MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript
    Motley Fool

    MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript

    MNKD earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights

    2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018  º  2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018  º  2Q 2019 Collaboration and Services Revenue was.

  • GlobeNewswire

    MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform

    WESTLAKE VILLAGE, Calif., Aug. 05, 2019 -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to.

  • GlobeNewswire

    MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019

    MannKind Corporation (MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 7, 2019. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

  • GlobeNewswire

    Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3

    MannKind Corporation (MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age (Cohort 3) and nearing completion for Cohort 2 (8-12 years of age). An interim review of data from individuals participating in the second cohort shows that the single‑dose pharmacokinetic profile of insulin levels for this age group is consistent with the pattern seen in adults. In addition, dosing over one month demonstrated a safety profile that was also consistent with that observed in adults.  As a result of these findings, MannKind and the study investigators are proceeding with enrollment of the third cohort of subjects.

  • GlobeNewswire

    MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants

    WESTLAKE VILLAGE, Calif., July 18, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0.

  • GlobeNewswire

    MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients

    WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) --  MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.

  • GlobeNewswire

    MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility.  This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.

  • What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?
    Simply Wall St.

    What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?

    If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...

  • Zacks Small Cap Research

    MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses

    New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.

  • GlobeNewswire

    MannKind to Present at the JMP Securities Life Sciences Conference

    WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • GlobeNewswire

    MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions

    MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10.  This study is the first step in preparation for a phase 3 safety and efficacy study.

  • GlobeNewswire

    Afrezza® (insulin human) Inhalation Powder Approved in Brazil

    Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).

  • 2 Healthcare Stocks That Could Double Your Money
    Motley Fool

    2 Healthcare Stocks That Could Double Your Money

    Should you be as excited as the analysts who think these stocks are two-baggers in the making?

  • Benzinga

    The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...

  • GlobeNewswire

    MannKind Announces Afrezza® Distribution Agreement in Australia

    MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.

  • Why MannKind Is Up Big Today
    Motley Fool

    Why MannKind Is Up Big Today

    Shares rise after the company receives some praise from a pair of Wall Street analysts.